Saniona: Milestone for the Ion Channel Platform

Redeye recognizes a milestone and signal value that SAN711 has entered a phase 1 clinical study.

AH

Anders Hedlund

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.